2d
a
10
1e
e
c
26
4e
16
11
19
1
49
2
12
1b
1d
18
2e
5a
1d
2 29
1d
25
Stuart N. Isaacs
78
5a
Associate Professor of Medicine (Infectious Diseases)
7
5f
Department: Medicine
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
6b
4
3
3
1d
6b
Perelman School of Medicine at the University of Pennsylvania
27 Division of Infectious Diseases
3c 319 Johnson Pavilion
Philadelphia, PA 19104-6073
26
27 Division of Infectious Diseases
3c 319 Johnson Pavilion
Philadelphia, PA 19104-6073
2e
Office: 215-573-7515
32 Fax: 215-349-5111
24
9b
12
32 Fax: 215-349-5111
24
18
Publications
23 a
3
2
29
23 a
Links
a7 Search PubMed for articles
9e Cell and Molecular Biology graduate group webpage
b6 Department of Medicine Division of Infectious Disease webpage
c
4
b
1f
a7 Search PubMed for articles
9e Cell and Molecular Biology graduate group webpage
b6 Department of Medicine Division of Infectious Disease webpage
c
13
Education:
21 9 B.A. 1e (Chemistry/Biology) c
2c Brandeis University, 1981.
21 9 M.D. 15 (Medicine) c
3b Yale University School of Medicine, 1985.
c
3
3
3
3
90
Permanent link21 9 B.A. 1e (Chemistry/Biology) c
2c Brandeis University, 1981.
21 9 M.D. 15 (Medicine) c
3b Yale University School of Medicine, 1985.
c
2 29
21
1e
1d
24
5e
55 Viral pathogenesis and viral evasion strategies from the host immune response
37 Recombinant vaccinia viruses as vaccine vectors
3a Counter-bioterrorism research focusing on smallpox
11 Monkeypox
1d Molluscum contagiosum
8
19 Key words:
8e Vaccinia virus, Recombinant vaccines, poxvirus , pathogenesis, smallpox and monkeypox vaccines and therapeutics, molluscum contagiosum
8
26 Description of Research
488 Dr. Isaacs' laboratory focuses on using poxviruses as a model system to study viral proteins that are involved in viral pathogenesis, dissemination, and evasion of the host immune response. Poxviruses, which are used widely as a tool for research and vaccine development, express proteins that inhibit complement activation, bind IL-1, TNF, and interferons, and decrease the host inflammatory response by other mechanisms. Elucidation of these processes could lead to a safer virus vector. Furthermore, the study of these defense molecules encoded by the virus might give insights into the control of inflammation, as well as, the development of new anti-inflammatory drugs. The laboratory has also been pursuing future generation subunit poxvirus vaccines. The lab has been studying protein/adjuvant and mRNA/lipid nanoparticle platforms. Dr. Isaacs was the poxvirus program project leader for the NIH-funded Middle Atlantic Regional Center of Excellence in Biodefense and Emerging Infectious Diseases and was involved in developing a safer smallpox vaccines as well as therapies to treat smallpox and complications from the current smallpox vaccine.
8
134 The Isaacs lab is also working with molluscum contagiosum, a poxvirus that causes a very common skin infection, especially in children. This virus has been difficult to study because it cannot be grown in cell culture. The Isaacs lab is pursuing approaches to grow this virus in cell culture systems.
8
eb At the VA, Dr, Isaacs is the Local Site investigator for a VA-wide cooperative studies program (CSP) titled "Epidemiology, Immunology, and Clinical Characteristics of COVID-19 (EPIC3) within the Veterans Health Administration."
8
8
1e Lab personnel:
13 Yuhong Xiao
8
23 Past lab personnel:
13 Asha Abdool
18 Edward Alexander
12 Jeanie Chu
12 Matt Cohen
15 Brian DeHaven
f Xin Fan
16 Natasha Girgis
19 Elizabeth Herrara
13 Heesun Kwak
17 Shamim Mohammad
14 Kendra Viner
15 Jessica Weaver
65
1a 29
27
Description of Research Expertise
2b Research Interests55 Viral pathogenesis and viral evasion strategies from the host immune response
37 Recombinant vaccinia viruses as vaccine vectors
3a Counter-bioterrorism research focusing on smallpox
11 Monkeypox
1d Molluscum contagiosum
8
19 Key words:
8e Vaccinia virus, Recombinant vaccines, poxvirus , pathogenesis, smallpox and monkeypox vaccines and therapeutics, molluscum contagiosum
8
26 Description of Research
488 Dr. Isaacs' laboratory focuses on using poxviruses as a model system to study viral proteins that are involved in viral pathogenesis, dissemination, and evasion of the host immune response. Poxviruses, which are used widely as a tool for research and vaccine development, express proteins that inhibit complement activation, bind IL-1, TNF, and interferons, and decrease the host inflammatory response by other mechanisms. Elucidation of these processes could lead to a safer virus vector. Furthermore, the study of these defense molecules encoded by the virus might give insights into the control of inflammation, as well as, the development of new anti-inflammatory drugs. The laboratory has also been pursuing future generation subunit poxvirus vaccines. The lab has been studying protein/adjuvant and mRNA/lipid nanoparticle platforms. Dr. Isaacs was the poxvirus program project leader for the NIH-funded Middle Atlantic Regional Center of Excellence in Biodefense and Emerging Infectious Diseases and was involved in developing a safer smallpox vaccines as well as therapies to treat smallpox and complications from the current smallpox vaccine.
8
134 The Isaacs lab is also working with molluscum contagiosum, a poxvirus that causes a very common skin infection, especially in children. This virus has been difficult to study because it cannot be grown in cell culture. The Isaacs lab is pursuing approaches to grow this virus in cell culture systems.
8
eb At the VA, Dr, Isaacs is the Local Site investigator for a VA-wide cooperative studies program (CSP) titled "Epidemiology, Immunology, and Clinical Characteristics of COVID-19 (EPIC3) within the Veterans Health Administration."
8
8
1e Lab personnel:
13 Yuhong Xiao
8
23 Past lab personnel:
13 Asha Abdool
18 Edward Alexander
12 Jeanie Chu
12 Matt Cohen
15 Brian DeHaven
f Xin Fan
16 Natasha Girgis
19 Elizabeth Herrara
13 Heesun Kwak
17 Shamim Mohammad
14 Kendra Viner
15 Jessica Weaver
65
Description of Clinical Expertise
2b General Infectious Diseases1a 29
23
254 Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ, Campos-Outcalt D, Morgan RL, Damon I, Sánchez PJ, Bell BB: Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep 71(22): 734-742, May 2022 Notes: https://www.cdc.gov/mmwr/volumes/71/wr/mm7122e1.htm?s_cid=mm7122e1_w#T3_down.
16e Xiao, Y.,Zeng, Y., Schande, C., Joshi, S.B., Buchman, G.W., Volkin, D.B., Middaugh, C.R., Isaacs, S.N.: Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus 3 3d Vaccine 38(38): 6007-6018, Aug 2020.
c4 Isaacs, S.N.: Monkeypox. UpToDate. Hirsch, M.S. (Section Editor); Mitty, J. (Deputy Editor) (eds.). Waltham, MA, June 2021.
177 Nuth M, Guan H, Xiao Y, Kulp JL, Parker MH, Strobel ED, Isaacs SN, Scott RW, Reitz AB, Ricciardi RP: Mutation and structure guided discovery of an antiviral small molecule that mimics an essential C-terminal tripeptide of the vaccinia D4 processivity factor. Antiviral Research 162: 178-185, Feb 2019.
1a0 Guan, H., Nuth, M., Zhukovskaya, N., Saw, Y.L., Bell, E., Isaacs, S.N., Ricciardi, R.P.: A novel target and approach for identifying antivirals against molluscum contagiosum virus. Antimicrobial Agents and Chemotherapy 58(12): 7383-9, Dec 2014 Notes: My lab made and tested the recombinant vaccinia virus that was critical to this publication.
18a Xiao, Y., Zeng, Y., Alexander, E., Mehta, S., Joshi, S.B., Buchman, G.W., Volkin, D.B., Middaugh, C.R., Isaacs, S.N.: Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge. Vaccine 31(2): 319-326, Jan 2013.
11c Hudson, P.N., Self, J., Weiss, S., Braden, Z., Xiao, Y., Girgis, N.M., Emerson, G., Hughes, C., Sammons, S.A., Isaacs, S.N., Damon, I.K., Olson, V.A.: Elucidating the role of the complement control protein in monkeypox pathogenicity. 2 39 PLoS One 7(4): e35086, Apr 2012.
1a1 Girgis, N.M., DeHaven, B.C., Xiao, Y., Alexander, E., Viner, K.M., Isaacs, S.N.: The vaccinia virus complement control protein modulates adaptive immune responses during infection. Journal of Virology 85(6): 2547-56, Mar 2011 Notes: Selected by Editors of Journal of Virology for "Spotlight Feature", which highlights 5 articles as meritorious.
cf Weaver JR, Isaacs SN: Monkeypox virus and insights into its immunomodulatory proteins. Immunological Reviews 225(1): 96-113, Oct 2008.
164 Buchman, G.W., Cohen, M.E., Xiao, Y., Richardson-Harman, N., Silvera, P., DeTolla, L.J., Davis, H.J., Eisenberg, R.J., Cohen, G.H., Isaacs, S.N. : A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 28(40): 6627-36, Sep 2010.
104 Cohen ME, Xiao Y, Eisenberg RJ, Cohen GH, Isaacs SN: Antibody against Extracellular Vaccinia Virus (EV) Protects Mice through Complement and Fc Receptors. PLoS ONE 6(6): e20597, Jun 2011.
2c
7
1d
1f
Selected Publications
fa Isaacs SN: Asymptomatic Infection? Another Reason to Consider Monkeypox a Disease of Public Health Concern. Ann Intern Med Aug 2022 Notes: 10.7326/M22-2457. Epub ahead of print.254 Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ, Campos-Outcalt D, Morgan RL, Damon I, Sánchez PJ, Bell BB: Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep 71(22): 734-742, May 2022 Notes: https://www.cdc.gov/mmwr/volumes/71/wr/mm7122e1.htm?s_cid=mm7122e1_w#T3_down.
16e Xiao, Y.,Zeng, Y., Schande, C., Joshi, S.B., Buchman, G.W., Volkin, D.B., Middaugh, C.R., Isaacs, S.N.: Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus 3 3d Vaccine 38(38): 6007-6018, Aug 2020.
c4 Isaacs, S.N.: Monkeypox. UpToDate. Hirsch, M.S. (Section Editor); Mitty, J. (Deputy Editor) (eds.). Waltham, MA, June 2021.
177 Nuth M, Guan H, Xiao Y, Kulp JL, Parker MH, Strobel ED, Isaacs SN, Scott RW, Reitz AB, Ricciardi RP: Mutation and structure guided discovery of an antiviral small molecule that mimics an essential C-terminal tripeptide of the vaccinia D4 processivity factor. Antiviral Research 162: 178-185, Feb 2019.
1a0 Guan, H., Nuth, M., Zhukovskaya, N., Saw, Y.L., Bell, E., Isaacs, S.N., Ricciardi, R.P.: A novel target and approach for identifying antivirals against molluscum contagiosum virus. Antimicrobial Agents and Chemotherapy 58(12): 7383-9, Dec 2014 Notes: My lab made and tested the recombinant vaccinia virus that was critical to this publication.
18a Xiao, Y., Zeng, Y., Alexander, E., Mehta, S., Joshi, S.B., Buchman, G.W., Volkin, D.B., Middaugh, C.R., Isaacs, S.N.: Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge. Vaccine 31(2): 319-326, Jan 2013.
11c Hudson, P.N., Self, J., Weiss, S., Braden, Z., Xiao, Y., Girgis, N.M., Emerson, G., Hughes, C., Sammons, S.A., Isaacs, S.N., Damon, I.K., Olson, V.A.: Elucidating the role of the complement control protein in monkeypox pathogenicity. 2 39 PLoS One 7(4): e35086, Apr 2012.
1a1 Girgis, N.M., DeHaven, B.C., Xiao, Y., Alexander, E., Viner, K.M., Isaacs, S.N.: The vaccinia virus complement control protein modulates adaptive immune responses during infection. Journal of Virology 85(6): 2547-56, Mar 2011 Notes: Selected by Editors of Journal of Virology for "Spotlight Feature", which highlights 5 articles as meritorious.
cf Weaver JR, Isaacs SN: Monkeypox virus and insights into its immunomodulatory proteins. Immunological Reviews 225(1): 96-113, Oct 2008.
164 Buchman, G.W., Cohen, M.E., Xiao, Y., Richardson-Harman, N., Silvera, P., DeTolla, L.J., Davis, H.J., Eisenberg, R.J., Cohen, G.H., Isaacs, S.N. : A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 28(40): 6627-36, Sep 2010.
104 Cohen ME, Xiao Y, Eisenberg RJ, Cohen GH, Isaacs SN: Antibody against Extracellular Vaccinia Virus (EV) Protects Mice through Complement and Fc Receptors. PLoS ONE 6(6): e20597, Jun 2011.
2c